210 related articles for article (PubMed ID: 8423625)
21. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
[TBL] [Abstract][Full Text] [Related]
22. Intratumoral interferon-alpha gene transfer enhances tumor immunity after allogeneic hematopoietic stem cell transplantation.
Hara H; Kobayashi A; Narumi K; Kondoh A; Yoshida K; Nishimoto T; Ohashi M; Higashihara E; Ohnami S; Yoshida T; Aoki K
Cancer Immunol Immunother; 2009 Jul; 58(7):1007-21. PubMed ID: 18998126
[TBL] [Abstract][Full Text] [Related]
23. In vivo cytokine gene transfer by gene gun reduces tumor growth in mice.
Sun WH; Burkholder JK; Sun J; Culp J; Turner J; Lu XG; Pugh TD; Ershler WB; Yang NS
Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2889-93. PubMed ID: 7708743
[TBL] [Abstract][Full Text] [Related]
24. Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth.
Ghosh P; Komschlies KL; Cippitelli M; Longo DL; Subleski J; Ye J; Sica A; Young HA; Wiltrout RH; Ochoa AC
J Natl Cancer Inst; 1995 Oct; 87(19):1478-83. PubMed ID: 7674335
[TBL] [Abstract][Full Text] [Related]
25. The prognostic significance of immune changes in patients with renal cell carcinoma treated with interferon alfa-2b.
Kosmidis PA; Baxevanis CN; Tsavaris N; Papanastasiou M; Anastasopoulos E; Bacoyiannis C; Mylonakis N; Karvounis N; Bafaloukos D; Karabelis A
J Clin Oncol; 1992 Jul; 10(7):1153-7. PubMed ID: 1535102
[TBL] [Abstract][Full Text] [Related]
26. [Lymphokine-activated killer (LAK) therapy for advanced renal cell carcinoma: clinical study on arterial LAK therapy and experimental study on LAK cell activity].
Hayakawa M
Hinyokika Kiyo; 1992 Nov; 38(11):1311-8. PubMed ID: 1485587
[TBL] [Abstract][Full Text] [Related]
27. Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients.
Schwaab T; Schwarzer A; Wolf B; Crocenzi TS; Seigne JD; Crosby NA; Cole BF; Fisher JL; Uhlenhake JC; Mellinger D; Foster C; Szczepiorkowski ZM; Webber SM; Schned AR; Harris RD; Barth RJ; Heaney JA; Noelle RJ; Ernstoff MS
Clin Cancer Res; 2009 Aug; 15(15):4986-92. PubMed ID: 19622576
[TBL] [Abstract][Full Text] [Related]
28. Induction of antitumor immunity and treatment of preestablished tumor by interleukin-6-gene-transfected melanoma cells combined with low-dose interleukin-2.
Cao X; Zhang W; Gu S; Yu Y; Tao Q; Ye T
J Cancer Res Clin Oncol; 1995; 121(12):721-8. PubMed ID: 7499443
[TBL] [Abstract][Full Text] [Related]
29. Interleukin-6 and renal cell cancer: production, regulation, and growth effects.
Koo AS; Armstrong C; Bochner B; Shimabukuro T; Tso CL; deKernion JB; Belldegrum A
Cancer Immunol Immunother; 1992; 35(2):97-105. PubMed ID: 1596939
[TBL] [Abstract][Full Text] [Related]
30. Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes.
Maeurer MJ; Martin DM; Castelli C; Elder E; Leder G; Storkus WJ; Lotze MT
Cancer Immunol Immunother; 1995 Aug; 41(2):111-21. PubMed ID: 7656270
[TBL] [Abstract][Full Text] [Related]
31. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.
Golumbek PT; Lazenby AJ; Levitsky HI; Jaffee LM; Karasuyama H; Baker M; Pardoll DM
Science; 1991 Nov; 254(5032):713-6. PubMed ID: 1948050
[TBL] [Abstract][Full Text] [Related]
32. [A new interferon-alpha assay system including indirect antitumor effect. Basic and clinical study of renal cell carcinoma].
Yoshihiro S
Nihon Hinyokika Gakkai Zasshi; 1992 Mar; 83(3):338-47. PubMed ID: 1564836
[TBL] [Abstract][Full Text] [Related]
33. Interferon-alpha and interleukin-12 gene therapy of cancer: interferon-alpha induces tumor-specific immune responses while interleukin-12 stimulates non-specific killing.
Eguchi J; Hiroishi K; Ishii S; Mitamura K
Cancer Immunol Immunother; 2003 Jun; 52(6):378-86. PubMed ID: 12739068
[TBL] [Abstract][Full Text] [Related]
34. Treatment of malignant melanoma and renal cell carcinoma with recombinant human interleukin-2: analysis of cytokine levels in sera and culture supernatants.
McIntyre CA; Chapman K; Reeder S; Dorreen MS; Bruce L; Rodgers S; Hayat K; Schreenivasan T; Sheridan E; Hancock BW
Eur J Cancer; 1992; 28(1):58-63. PubMed ID: 1567693
[TBL] [Abstract][Full Text] [Related]
35. Interferon-alpha-induced protection of renal cell cancer cell line from lysis by natural killer cells and increase of susceptibility by treatment with 5-fluorouracil.
Imai T; Katagiri A; Saito K; Tomita Y
Cancer Lett; 1995 Aug; 94(2):191-7. PubMed ID: 7634247
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-2 and interferon in renal cell carcinoma.
Wersäll P
Med Oncol Tumor Pharmacother; 1993; 10(1-2):71-6. PubMed ID: 7505042
[TBL] [Abstract][Full Text] [Related]
37. Interferon-alpha enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models.
Kawai S; Azuma Y; Fujii E; Furugaki K; Ozaki S; Matsumoto T; Kosaka M; Yamada-Okabe H
Cancer Sci; 2008 Dec; 99(12):2461-6. PubMed ID: 19032371
[TBL] [Abstract][Full Text] [Related]
38. Rapid cytokine release in cancer patients treated with interleukin-2.
Weidmann E; Bergmann L; Stock J; Kirsten R; Mitrou PS
J Immunother (1991); 1992 Aug; 12(2):123-31. PubMed ID: 1504053
[TBL] [Abstract][Full Text] [Related]
39. Human lung tumor cell secretion of interleukin-2 for protection against tumor engraftment.
Alosco T; Gansbacher B; Bankert R; Takita H; Petrelli N
Ann Surg Oncol; 1994 May; 1(3):229-35. PubMed ID: 7842293
[TBL] [Abstract][Full Text] [Related]
40. Combination therapy for renal cell carcinoma using IFN-gamma and OK-432: in vitro study.
Muraki J
Keio J Med; 1990 Mar; 39(1):21-5. PubMed ID: 2113148
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
